TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03631017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]- PARPi
Description: injection of a microdose (\< 100 ug) of \[18F\]- PARPi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]- PARPi
Description: injection of a microdose (\< 100 ug) of \[18F\]- PARPi

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Scans
Description: Patients will be injected with approximately 10 mCi of \[18F\]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use ultra -low dose CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Scans
Description: Patients will be injected with approximately 10 mCi of \[18F\]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use ultra -low dose CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings.
Study: NCT01591356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EphA2-targeting DOPC-encapsulated siRNA
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03637660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzathine Penicillin
Description: BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzathine Penicillin
Description: BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
Study: NCT04645680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume isocaloric whole foods diet higher in fiber

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Whole foods diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03629678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobile health application
Description: The user-driven technological tool will include an mHealth mobile phone application. Features of the application will be based on preliminary work from the investigators' sites. The mobile app will include fully searchable provider-facing and patient-facing interfaces with the SCD-specific guidelines. The provider-facing interface, designed to be used by providers, will be separated by patient's age to accommodate pediatric and adult providers. The patient-facing interface will display the guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and text-message reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
Study: NCT02761057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of plasma and serum samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of plasma and serum samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of plasma and serum samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of plasma and serum samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study: NCT01444300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: 10mg, bid, pill taken by mouth for 12 weeks
Study: NCT02761057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT01444300

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill, bid for 12 weeks
Study: NCT02761057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study: NCT03151486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 0.5 mg
Description: Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 1.5 mg
Description: Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
Study: NCT02761057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT03849820

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-assisted partial nephrectomy
Description: Application of the da Vinci surgical robot to assist the partial nephrectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open partial nephrectomy
Description: Open surgery to conduct the partial nephrectomy
Study: NCT04721912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic dietary supplement
Description: GBS positive patients, at ≥ 36 weeks gestation, will begin taking oral Florajen Digestion probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth.
Study: NCT03151486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 4 mg
Description: Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
Study: NCT04533529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant tablet will be administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet will be administered orally once daily.
Study: NCT03151486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 12 mg
Description: Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
Study: NCT04030455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02079662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Undergo IO intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention
Description: Undergo IO intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Undergo IO intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo IO intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04801264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga-PSMA will be used to image lesions of adenoid cystic carcinoma by PET/CT.
Study: NCT03961672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Given PO
Study: NCT03538041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally.
Study: NCT04801264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
Description: Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Study: NCT00643084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low residue diet/no standard bowel preparation
Description: low residue diet/no standard bowel preparation
Study: NCT03151486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 36 mg
Description: Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942 100 mg
Description: Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942: Fed State
Description: Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942: MAD Part
Description: Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942: MAD Part
Description: Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942: MAD Part
Description: Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.
Study: NCT00490542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone (Geodon)
Description: ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
Study: NCT04641897

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Respiratory rate modification
Description: During the Low RR and High RR periods, respiratory rate will be set depending on baseline ABG and according a nomogram so as to have an approximate difference of 10 points between groups, while maintining PaCO2 and pH values within safety limits (pH 7.20 to 7.45, and PaCO2 35 to 60 mmHg).~Once defined the target respiratory rate, this will be decreased or increased in 4 points each 30 to 45 min, and ABG repeated at 2 hours. At this time, changes will be made to keep PaCO2 and pH values within safety limits, and ABG repeated at 6 and finally 12 hours.~During the whole period, inspiratory to expiratory ratio will be maintained constant, and only changed to keep inspiratory time above 0.6 seconds (usually at high resp rate).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Respiratory rate modification
Description: During the Low RR and High RR periods, respiratory rate will be set depending on baseline ABG and according a nomogram so as to have an approximate difference of 10 points between groups, while maintining PaCO2 and pH values within safety limits (pH 7.20 to 7.45, and PaCO2 35 to 60 mmHg).~Once defined the target respiratory rate, this will be decreased or increased in 4 points each 30 to 45 min, and ABG repeated at 2 hours. At this time, changes will be made to keep PaCO2 and pH values within safety limits, and ABG repeated at 6 and finally 12 hours.~During the whole period, inspiratory to expiratory ratio will be maintained constant, and only changed to keep inspiratory time above 0.6 seconds (usually at high resp rate).
Study: NCT02027909

Intervention type: DEVICE
Intervention: Reprogramming dual chamber pacemaker
Description: Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover

Intervention type: DEVICE
Intervention: Reprogramming dual chamber pacemaker
Description: Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
Study: NCT00643084

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard bowel preparation
Description: standard bowel preparation
Study: NCT02027909

Intervention type: DEVICE
Intervention: Reprogramming dual chamber pacemaker
Description: Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
Study: NCT01741844

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
Study: NCT01162226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gait and balance training program
Description: The intervention will be implemented via three 50-minute training sessions per week for 12 weeks. The games will be played when the subject is receiving the maximum benefit from their anti-parkinsonian medications. The control group and the intervention group will receive weekly telephone calls to inquire about medications and falls. At baseline and end of the 12 weeks, in-home testing will determine stride length and speed; standing balance eyes open and closed on flat and foam surface.
Study: NCT00414765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Study: NCT02171637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: escalating doses
Study: NCT03533270

Intervention type: PROCEDURE
Intervention: Urethroplasty
Description: Surgical repair of Urethral injury
Study: NCT03555305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Administered SC
Study: NCT03642769

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid administration
Description: Fluid administration of bolus and maintenance fluids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid administration
Description: Fluid administration of bolus and maintenance fluids
Study: NCT03928886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bilateral two-view (CC and MLO) FFDM (full field digital mammography) using patient-assisted compression mode
Description: Patient-assisted mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral two-view (CC and MLO) FFDM (full field digital mammography) using standard compression mode
Description: Standard compression mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure.~Study-related compressions will consist of the first and second CC and MLO compressions performed on each breast during each subject's exam.
Study: NCT00259012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole sodium enteric-coated spheroid suspension
Description: pediatric suspension taken daily x 7 days
Study: NCT00490542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
Study: NCT03488667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab
Description: Pembrolizumab, mFOLFOX Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Treatment - mFOLFOX & Pembrolizumab
Description: Pembrolizumab, mFOLFOX Chemotherapy
Study: NCT01868529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
Study: NCT00033865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga, Relaxation Exercises, Sleep Hygiene
Description: Sleep hygiene and relaxation exercises, with additional yoga
Study: NCT02293122

Intervention type: OTHER
Intervention: Observational
Description: Intervention is observational to two different diagnostic devices for which comparative readings of the corneal endothelium are being measured; the test device- the EM-3000 Specular Microscope against the Konan Robo-pachy F\&A Specular Microscope.
Study: NCT01868529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
Study: NCT01185548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasisulam
Description: Administered intravenously